earnings
confidence high
sentiment neutral
materiality 0.60
ReShape Lifesciences Q1 rev $1.9M (-15% YoY), gross margin up to 59.9%, opex down 51%
Vyome Holdings, Inc
2024-Q1 EPS
reported -$0.09
vs consensus -$946.56
▲ beat
(+100.0%)
- Q1 revenue $1.9M, down 15% YoY; gross margin improved to 59.9% (from 53.5%) due to lower overhead.
- Total operating expenses down 51% YoY; sales & marketing down 53%, G&A down 56%.
- Cost reduction plan expected to cut 2024 opex by ~55% vs 2023; RIF implemented.
- Cash and equivalents $2.5M; net working capital $4.4M.
- Lap-Band 2.0 FLEX launch underway; intragastric balloon patent issued; M&A search with Maxim Group.